The CASP6 Knockout NCI-H1703 Polyclonal Cells product is a polyclonal knockout cell population generated by CRISPR/Cas9-mediated disruption of the human CASP6 gene in the NCI-H1703 host cell line. This polyclonal knockout pool provides a loss-of-function model for investigating the biological roles of caspase-6, an executioner caspase central to apoptotic execution. As a polyclonal population, the cells retain genetic heterogeneity at the targeted locus, offering a versatile tool for studying gene function without the limitations of clonal selection. The knockout cells are designed for use in a wide range of functional studies, including apoptosis signaling, drug response profiling, and mechanistic dissection of cell death pathways.
The NCI-H1703 host cell line is a widely used human non-small cell lung cancer (NSCLC) line derived from a squamous cell carcinoma in a 54-year-old male patient. These cells exhibit adherent epithelial morphology and harbor a mutation in the tumor suppressor p53, a critical regulator of apoptosis and cell cycle arrest. NCI-H1703 cells are extensively employed as a model system for lung cancer biology, particularly for studies involving tumor proliferation, invasion, and response to chemotherapeutic agents. The genetic background of this cell line, including the p53 mutation, makes it a suitable platform for examining how alterations in apoptotic execution affect cancer cell survival and drug sensitivity.
CASP6 encodes caspase-6, an executioner caspase that functions downstream of initiator caspases such as caspase-8 and caspase-9 in both the extrinsic and intrinsic apoptosis pathways. Upon activation, typically through proteolytic cleavage by upstream initiator caspases in response to death receptor signaling (e.g., FAS/FADD/caspase-8) or mitochondrial cytochrome c release and Apaf-1 apoptosome formation (caspase-9), caspase-6 cleaves specific substrates including nuclear lamins (LMNA, LMNB), PARP, and ICAD. These cleavage events contribute to nuclear envelope breakdown, chromatin condensation, and cell dismantling. Caspase-6 activity is regulated by interactions with inhibitor-of-apoptosis proteins (IAPs) such as XIAP and is modulated by Bcl-2 family proteins at the mitochondrial level. The enzyme is also implicated in non-apoptotic roles, including neuroinflammation and neurodegeneration, linking it to diseases beyond cancer.
In the lung cancer context, disruption of CASP6 in NCI-H1703 cells creates a valuable model for studying apoptosis resistance. Given the host cell’s p53 mutation, which already impairs some apoptotic signaling, the loss of caspase-6 further attenuates the execution phase of cell death. This double perturbation may enhance cell survival and confer resistance to chemotherapeutic drugs that rely on apoptosis induction, such as platinum-based agents commonly used in NSCLC treatment. Consequently, the CASP6 knockout NCI-H1703 polyclonal cells are particularly relevant for investigating mechanisms of drug resistance in squamous cell lung carcinoma and for screening compounds that can bypass caspase-6-dependent apoptosis.
These polyclonal knockout cells are ideal for a broad spectrum of research applications. They can be used to dissect apoptosis signaling networks through caspase activity assays, western blotting for cleaved substrates (e.g., lamin A/C, PARP), and apoptosis induction experiments with death ligands or chemotherapeutics. Additionally, cell viability and drug sensitivity assays enable systematic evaluation of chemoresistance mechanisms, while migration and invasion assays facilitate studies on the interplay between apoptosis and metastatic potential. The cells are also suited for functional genomics screens and protein?Cprotein interaction analyses to identify novel regulators or interacting partners of caspase-6. For further information or to discuss custom applications, please contact Ascent Research.
